FindTrial
Sign In

A study of the safety and sustainability of pain therapy with conditioned medium

Study on the safety and sustained efficacy of pain Treatment with human adipose-derived mesenchymal stem cell conditioned medium in patients with Osteoarthritis and Rheumatoid Arthritis.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1050230092
Enrollment
Unknown
Registered
2023-08-30
Start date
2023-10-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain Osteoarthritis Rheumatoid Arthritis

Interventions

None listed

Sponsors

Taketomi Masanori
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged over 18 years old. 2. Patients who can obtain written consent of the person's free will. 3. Patients for whom the attending physician has recognized the necessity of the treatment.

Exclusion criteria

Exclusion criteria: 1. Patients without pain other than psychogenic pain. 2. Patients Those who are allergic to gentamicin. 3. Patients who use narcotics or stimulants. 4. Patients who do not provide understanding and consent regarding this treatment. 5. Pregnant patients. 6. Patients who clearly cannot continue to visit the clinic during or after treatment 7. Other patients deemed inappropriate by the attending physician.

Design outcomes

Primary

MeasureTime frame
1. Pain location. 2. Presence of joint effusion. 3. Pain intensity (VAS - Visual Analog Scale). 4. Effect of pain on daily functional activities (m-HAQ - modified Health Assessment Questionnaire). 5. KL classification (for osteoarthritis cases only).—

Contacts

Public ContactMasanori Taketomi

Taketomi Clinic

m.taketomi.clinic.jrct@gmail.com+81-78-232-7277

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026